News & Updates

Show Multimedia Only

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

17 May 2021 by

The RNAi* therapeutic agent lumasiran demonstrated favourable clinical outcomes for primary hyperoxaluria type 1 (PH1) in both paediatric and adult patients, according to the results of the phase III ILLUMINATE-A and ILLUMINATE-B trials presented at PAS 2021.

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

17 May 2021

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021 by

Updated analyses of the phase III IMvigor130 trial presented at AACR 2021 revealed the overall survival (OS) benefit of atezolizumab for previously untreated locally advanced or metastatic urothelial carcinoma (mUC), be it alone or with platinum/gemcitabine chemotherapy (CT).

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021

News & Updates

Showing Urology articles

Showing

Specialty:

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer